Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

416 ARTÍCULOS , VIENDO DEL 316 AL 330

Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers

Nho K, Kueider-Paisley A, Ahmad S, MahmoudianDehkordi S, Arnold M, Risacher SL, Louie G, Blach C, Baillie R, Han X, Kastenmüller G, Trojanowski JQ, Shaw LM, Weiner MW, Doraiswamy PM, van Duijn C, Saykin AJ, Kaddurah-Daouk R; Alzheimer’s Disease Neuroimaging Initiative and the Alzheimer Disease Metabolomics Consortium.

JAMA Netw Open. 2019 Jul 3;2(7):e197978. doi: 10.1001/jamanetworkopen.2019.7978.

Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study

Miebach L, Wolfsgruber S, Polcher A, Peters O, Menne F, Luther K, Incesoy E, Priller J, Spruth E, Altenstein S, Buerger K, Catak C, Janowitz D, Perneczky R, Utecht J, Laske C, Buchmann M, Schneider A, Fliessbach K, Kalbhen P, Heneka MT, Brosseron F, Spottke A, Roy N, Teipel SJ, Kilimann I, Wiltfang J, Bartels C, Düzel E, Dobisch L, Metzger C, Meiberth D, Ramirez A, Jessen F, Wagner M.

Alzheimers Res Ther. 2019 Jul 31;11(1):66. doi: 10.1186/s13195-019-0515-y.

Blood circulating miRNAs as biomarkers of Alzheimer's disease: a systematic review and meta-analysis

Zhang YH, Bai SF, Yan JQ.

Biomark Med. 2019 Aug;13(12):1045-1054. doi: 10.2217/bmm-2018-0341. Epub 2019 Aug 6.

Blood-based biomarkers for Down syndrome and Alzheimer's disease: A systematic review

Petersen ME, O'Bryant SE.

Dev Neurobiol. 2019 Jul;79(7):699-710. doi: 10.1002/dneu.22714. Epub 2019 Sep 3.

[New biomarkers for Alzheimer's disease in cerebrospinal fluid and blood]

Vogelgsang J, Wiltfang J.

Nervenarzt. 2019 Sep;90(9):907-913. doi: 10.1007/s00115-019-0772-9.

Cerebrospinal Fluid Correlates of Neuropsychiatric Symptoms in Patients with Alzheimer's Disease/Mild Cognitive Impairment: A Systematic Review

Showraki A, Murari G, Ismail Z, Barfett JJ, Fornazzari L, Munoz DG, Schweizer TA, Fischer CE.

J Alzheimers Dis. 2019;71(2):477-501. doi: 10.3233/JAD-190365.

Amyloid-β PET-Correlation with cerebrospinal fluid biomarkers and prediction of Alzheimer´s disease diagnosis in a memory clinic

Müller EG, Edwin TH, Stokke C, Navelsaker SS, Babovic A, Bogdanovic N, Knapskog AB, Revheim ME.

PLoS One. 2019 Aug 20;14(8):e0221365. doi: 10.1371/journal.pone.0221365. eCollection 2019.

AD biomarker discovery in CSF and in alternative matrices

Sancesario G, Bernardini S.

Clin Biochem. 2019 Oct;72:52-57. doi: 10.1016/j.clinbiochem.2019.08.008. Epub 2019 Aug 19.

The "rights" of precision drug development for Alzheimer's disease

Cummings J, Feldman HH, Scheltens P.

Alzheimers Res Ther. 2019 Aug 31;11(1):76. doi: 10.1186/s13195-019-0529-5.

Developing Effective Alzheimer's Disease Therapies: Clinical Experience and Future Directions

Elmaleh DR, Farlow MR, Conti PS, Tompkins RG, Kundakovic L, Tanzi RE.

J Alzheimers Dis. 2019;71(3):715-732. doi: 10.3233/JAD-190507.

A Pilot Study of Exenatide Actions in Alzheimer's Disease

Mullins RJ, Mustapic M, Chia CW, Carlson O, Gulyani S, Tran J, Li Y, Mattson MP, Resnick S, Egan JM, Greig NH, Kapogiannis D.

Curr Alzheimer Res. 2019;16(8):741-752. doi: 10.2174/1567205016666190913155950.

Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment

Chandra A, Valkimadi PE, Pagano G, Cousins O, Dervenoulas G, Politis M; Alzheimer's Disease Neuroimaging Initiative.

Hum Brain Mapp. 2019 Dec 15;40(18):5424-5442. doi: 10.1002/hbm.24782. Epub 2019 Sep 14.

Affective symptoms and AT(N) biomarkers in mild cognitive impairment and Alzheimer's disease: A systematic literature review

Banning LCP, Ramakers IHGB, Deckers K, Verhey FRJ, Aalten P.

Neurosci Biobehav Rev. 2019 Dec;107:346-359. doi: 10.1016/j.neubiorev.2019.09.014. Epub 2019 Sep 13.

Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease

Hadoux X, Hui F, Lim JKH, Masters CL, Pébay A, Chevalier S, Ha J, Loi S, Fowler CJ, Rowe C, Villemagne VL, Taylor EN, Fluke C, Soucy JP, Lesage F, Sylvestre JP, Rosa-Neto P, Mathotaarachchi S, Gauthier S, Nasreddine ZS, Arbour JD, Rhéaume MA, Beaulieu S, Dirani M, Nguyen CTO, Bui BV, Williamson R, Crowston JG, van Wijngaarden P.

Nat Commun. 2019 Sep 17;10(1):4227. doi: 10.1038/s41467-019-12242-1.

Perspective: Clinical relevance of the dichotomous classification of Alzheimer's disease biomarkers: Should there be a "gray zone"?

McRae-McKee K, Udeh-Momoh CT, Price G, Bajaj S, de Jager CA, Scott D, Hadjichrysanthou C, McNaughton E, Bracoud L, Ahmadi-Abhari S, de Wolf F, Anderson RM, Middleton LT; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2019 Oct;15(10):1348-1356. doi: 10.1016/j.jalz.2019.07.010. Epub 2019 Sep 26.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias